Government cuts could help spark surge in M&A activity
Reductions in staff at the FDA are putting pressure on biotech companies, especially those strapped for cash, and could lead to more M&A activity, according to Andrew Goodman, a partner in the M&A practice at business law firm Paul Hastings.
Reductions in staff at the FDA are putting pressure on biotech companies, especially those strapped for cash, and could lead to more M&A activity, according to Andrew Goodman, a partner in the M&A practice at business law firm Paul Hastings.
